BEXAR

BEXAR study is a Phase Ib/II trial that aims to evaluate if adding bexmarilimab (anti-CLEVER-1) to doxorubicin in patients with metastatic soft tissue sarcoma (STS) improves outcomes. It is composed by two phases:

-Phase Ib: Dose-escalation study to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of bexmarilimab in combination with doxorubicin.

-Phase II: Randomized 1:1 study comparing bexmarilimab plus doxorubicin versus doxorubicin alone as first-line treatment for advanced STS.

The primary objective is to assess whether adding bexmarilimab improves progression-free survival (PFS) compared with standard doxorubicin.